Farkasgyepui Tudogyogyintezet — Clinical Trial Site

25 Registered trials

11 Currently recruiting

Organisation

Farkasgyepui Tudogyogyintezet

Location

Farkasgyepu, Hungary

Identifier

ORG-100043030

Address

049 Hrsz 2, 8582, Hungary

Departments

1st Pulmonology
4706
Department of Pulmonology
Farkasgyepui Tudogyogyintezet
I Pulmonologia
I. es II. Pulmonologia
I. Pulmonologia
I. Pulmonology
III. Pulmonologia
N/A
Pulmonologia
Pulmonologiai
Pulmonology
Pulmunologia
Veszprem County Pulmonology Institute

Clinical trials at this site (25)

Search interface

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending

2024-518821-13-00 Non-cystic Fibrosis Bronchiectasis 4
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting

2024-514459-14-00 Non-Small Cell Lung Cancer 4 2025-04-22
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 non-squamous non-small cell lung cancer 5 2024-06-06
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of NSCLC Recruiting

2024-519883-42-00 Non-small cell lung cancer 5 2025-10-08
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting

2023-507778-42-00 Non-Small Cell Lung Cancer II, III 4 2023-03-08
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted

2023-508730-34-00 Non-small cell lung cancer (NSCLC): - Locally advanced 9 2024-07-10
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended

2022-501439-18-00 NSCLC with squamous or nonsquamous histology 5 2019-06-26